Your browser doesn't support javascript.
loading
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
Thng, Zheng Xian; Bromeo, Albert John; Mohammadi, S Saeed; Khatri, Anadi; Tran, Anh N T; Akhavanrezayat, Amir; T T Than, Ngoc; Nguyen, Khiem S; Yoo, Woong-Sun; Mobasserian, Azadeh; Or, Christopher Chi Mong; Nguyen, Quan Dong.
Afiliación
  • Thng ZX; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • Bromeo AJ; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.
  • Mohammadi SS; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • Khatri A; Asian Eye Institute, Makati, Philippines.
  • Tran ANT; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • Akhavanrezayat A; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • T T Than N; Birat Aankha Aspatal, Biratnagar, Nepal.
  • Nguyen KS; Department of Ophthalmology, Birat Medical College and Teaching Hospital, Kathmandu University, Biratnagar, Nepal.
  • Yoo WS; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • Mobasserian A; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • Or CCM; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
  • Nguyen QD; Byers Eye Institute, Stanford University, Palo Alto, California, USA.
Expert Opin Emerg Drugs ; 28(4): 297-309, 2023 12.
Article en En | MEDLINE | ID: mdl-38129984
ABSTRACT

INTRODUCTION:

Uveitis is a heterogeneous group of ocular conditions characterized by inflammation of the uveal tract. It is a leading cause of blindness in developed countries and exerts significant psychological, social, and economic impact on both patients and the larger society. While there are numerous pharmacotherapy options, posterior segment noninfectious uveitis remains a significant challenge to treat due to its severity, chronicity, and high recurrence rates. AREAS COVERED The index review highlights the unmet needs of uveitis pharmacotherapy and its research and the shortcomings of existing ocular and systemic therapeutic options for noninfectious uveitis. The more promising novel ocular drug delivery methods and therapeutic targets/drugs are discussed, and evidence from the clinical trials is evaluated. EXPERT OPINION There has been incredible growth in the number of treatment options available to uveitis patients today, especially with the new generation of biologic drugs. Available evidence suggests that these newer options may be superior to conventional immunosuppressive therapies in terms of efficacy and side effect profiles. Further high-quality research and additional clinical trials will be needed to clarify their roles in the stepladder treatment approach of noninfectious uveitis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis Límite: Humans Idioma: En Revista: Expert Opin Emerg Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Uveítis Límite: Humans Idioma: En Revista: Expert Opin Emerg Drugs Asunto de la revista: TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido